-
- Marc Lipsitch
- From the Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (M.L.); Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA (D.L.S.); and the Center for Observational and Real-World Evidence, Merck, Kenilworth, NJ (L.F.).
-
- David L. Swerdlow
- From the Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (M.L.); Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA (D.L.S.); and the Center for Observational and Real-World Evidence, Merck, Kenilworth, NJ (L.F.).
-
- Lyn Finelli
- From the Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (M.L.); Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, PA (D.L.S.); and the Center for Observational and Real-World Evidence, Merck, Kenilworth, NJ (L.F.).
収録刊行物
-
- New England Journal of Medicine
-
New England Journal of Medicine 382 (13), 1194-1196, 2020-03-26
Massachusetts Medical Society